Menu Search
Equities

Gyre Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
L9S:DUS

Gyre Therapeutics Inc

Actions
  • Price (EUR)6.55
  • Today's Change0.05 / 0.77%
  • Shares traded--
  • 1 Year change-39.91%
  • Beta1.9026
Data delayed at least 15 minutes, as of Feb 12 2026 08:31 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.

  • Revenue in USD (TTM)107.27m
  • Net income in USD6.65m
  • Incorporated1997
  • Employees574.00
  • Location
    Gyre Therapeutics Inc12770 High Bluff Drive, Suite 150SAN DIEGO 92130United StatesUSA
  • Phone+1 (858) 567-7770
  • Fax+1 (302) 636-5454
  • Websitehttps://www.gyretx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.